Cover Image
Market Research Report

Bromodomain Containing Protein 2 - Pipeline Review, H1 2020

Published by Global Markets Direct Product code 516025
Published Content info 70 Pages
Delivery time: 1-2 business days
Price
Back to Top
Bromodomain Containing Protein 2 - Pipeline Review, H1 2020
Published: February 28, 2020 Content info: 70 Pages
Description

Summary

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in spermatogenesis. It plays a role in the regulation of transcription, probably by chromatin remodeling and also plays a role in nucleosome assembly. It regulates transcription of the CCND1 gene.

Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 3 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Immunology, Musculoskeletal Disorders and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Fibrosis, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Leukemia, Lung Cancer, Multiple Myeloma (Kahler Disease), Myelofibrosis, Myeloproliferative Disorders, Non-Hodgkin Lymphoma, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Small-Cell Lung Cancer, Systemic Lupus Erythematosus and Vitiligo.

The latest report Bromodomain Containing Protein 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
  • The report reviews Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2269TDB

Table of Contents

List of Tables

List of Figures

Introduction

  • Global Markets Direct Report Coverage
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Overview
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Amgen Inc
  • Boston Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Constellation Pharmaceuticals Inc
  • Ningbo Wenda Pharma
  • Zenith Epigenetics Ltd
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Drug Profiles
  • ABBV-744 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BOS-475 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CC-95775 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CPI-0610 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NHWD-870 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NUE-19796 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NUE-20798 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NUE-7770 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • QCA-570 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZEN-3694 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Dormant Products
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Discontinued Products
  • Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 07, 2020: Zenith Epigenetics receives US$5 million milestone payment from Newsoara
  • Dec 19, 2019: Zenith Epigenetics announces clinical advancement of ZEN-3694
  • Dec 09, 2019: Constellation Pharmaceuticals provides updated preliminary data from MANIFEST clinical trial with CPI-0610 in oral and poster presentations at ASH
  • Dec 02, 2019: Constellation Pharmaceuticals to host analyst/investor meeting at ASH to discuss updated preliminary data from the MANIFEST clinical trial with CPI-0610
  • Nov 06, 2019: FORMA announces poster presentation on FT-1101 at upcoming 2019 ASH Annual Meeting
  • Oct 10, 2019: Constellation Pharmaceuticals announces MANIFEST data updates will be provided in oral and poster sessions on December 9 at ASH
  • Jun 27, 2019: Zenith Epigenetics announces dosing of first patient in triple negative breast cancer trial with Pfizer
  • Jun 03, 2019: Interim data for CPI-0610 in MANIFEST clinical trial showed signals of clinical activity in Myelofibrosis patients
  • May 23, 2019: Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial
  • May 16, 2019: Constellation Pharmaceuticals provides interim update of data for CPI-0610 in ASCO and EHA abstracts
  • May 09, 2019: Nuevolution's BET-BD1 selective inhibitor and candidate compound, NUE20798, shows positive effect on disease scoring and biomarker levels in an atopic dermatitis (eczema) mouse model
  • Mar 18, 2019: Zenith Epigenetics announces U.S. FDA clearance of investigational new drug application for ZEN-3694 in TNBC program
  • Feb 21, 2019: A Nuevolution BET-BD1 selective inhibitor shows potential anticancer effect with immunotherapy in a mouse model of colorectal cancer
  • Jan 03, 2019: Constellation Pharmaceuticals provides update on MANIFEST clinical trial of CPI-0610 in mlyelofibrosis
  • Nov 01, 2018: Constellation Pharmaceuticals receives FDA Fast Track Designation for CPI-0610 in treatment of Myelofibrosis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by AbbVie Inc, H1 2020
  • Pipeline by Amgen Inc, H1 2020
  • Pipeline by Boston Pharmaceuticals Inc, H1 2020
  • Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Pipeline by Constellation Pharmaceuticals Inc, H1 2020
  • Pipeline by Ningbo Wenda Pharma, H1 2020
  • Pipeline by Zenith Epigenetics Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
Back to Top